Arcus Biosciences And Summit Therapeutics Enter Into Clinical Trial Collaboration

July 22 (Reuters) - Arcus Biosciences Inc RCUS.N:

• Arcus Biosciences and Summit Therapeutics enter into clinical trial collaboration to evaluate casdatifan combined with ivonescimab in kidney cancer
• Under terms of agreement, Summit will supply ivonescimab and Arcus will conduct and sponsor combination study
• Both companies will contribute to cost of study, each company will retain development and commercial rights to their respective molecules
• Initial data from this clinical trial collaboration is expected to be generated by mid-2027